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1In the general population, the presence of obesity represents one of the most important risk factors for cardiovascular 
disease, cardiovascular death, and all-cause death.1 Indeed, 
body mass index (BMI) has a continuous positive relationship 
with CVD risk.2 All major international guidelines on CVD 
prevention recommend to attainment and maintenance of an 
healthy weight to achieve a reduction in cardiovascular risk 
and incident cardiovascular events.2,3
Despite this, an inverse relationship between overweight 
or obesity and a better cardiovascular prognosis in long-term 
follow-up studies has been observed, a phenomenon described 
as an obesity paradox.4,5 Several studies have found an obesity 
paradox is evident in patients with established cardiovascular 
disease, including hypertension, coronary heart disease, and 
chronic heart failure.6 An obesity paradox may also be evident 
in primary prevention patients.7
Atrial fibrillation (AF) is the commonest sustained cardiac 
arrhythmia, and the relationship between obesity and AF is 
well established. Several studies have reported epidemiologi-
cal, clinical, and mechanistic associations, clearly establishing 
a pathophysiological cause–effect relationship between obe-
sity and incident AF.8 Interventions aimed at weight reduction 
are associated with a reduction in the risk of developing AF.9,10 
In patients with established AF, an obesity paradox is also evi-
dent for the risk of developing major adverse events,11 even if 
this risk seems to be mitigated by a good-quality anticoagula-
tion control.12
To study this, we performed a systematic review and meta-
analysis with several objectives, as follows: (1) to provide a 
comprehensive report of all available evidence on the relation-
ship between overweight and obesity in AF patients; (2) to 
perform a comparative analysis of observational studies and 
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2  Stroke  April 2017
subgroup analyses from randomized clinical trials (RCTs); 
and (3) to conduct a meta-analysis of available data on the 
relationship of BMI to stroke/systemic embolic event (SEE) 
and major bleeding in the phase III non–vitamin K antagonist 
oral anticoagulant (NOAC) trials of stroke prevention in AF.
Methods
All prospective studies, both RCTs and observational, reporting data 
about AF and BMI categories were considered eligible for the sys-
tematic review. A comprehensive literature search was performed 
using PubMed and Scopus databases, up to June 30, 2016.
Data for meta-analysis were retrieved from original phase III tri-
als or from regulatory documentation. Data extraction and bias 
assessment were performed independently by 2 coauthors, with dis-
crepancies resolved by collegial discussion. All statistical analyses 
were undertaken using Review Manager (RevMan) version 5.3 (The 
Cochrane Collaboration 2014; Nordic Cochrane Center Copenhagen, 
Denmark). Full details of the literature search strategy, study selection 
criteria, quality assessment, and statistical analysis have been reported 
in the Methods section in the online-only Data Supplement. This work 
has been performed according to PRISMA guidelines (http://www.
prisma-statement.org; Table I in the online-only Data Supplement).
Results
Systematic Review
On the basis of our literature search (Figure 1), 13 studies ful-
filled our criteria, with details summarized in Table. Five were 
subgroup analyses of previously published RCTs,11–15 whereas 
the other 8 were observational studies.16–23 One study included 
AF patients who underwent an ablation procedure for rhythm 
control strategy.21 Four observational studies were based on 
Asian populations.17–19,23 In 12 out of 13 studies, the mean age 
progressively decreased with higher BMI categories, with the 
study by Overvad et al16 being the exception (Table).
In 2016 alone, 6 other studies were published examining the 
relationship of BMI with outcomes in AF. Three were obser-
vational studies,20–22 whereas the others were RCTs focused 
on comparisons between vitamin K antagonist and alternative 
anticoagulants.12,14,15
RCT Cohorts
Two separate studies reported subgroup analysis from the 
AFFIRM study (Atrial Fibrillation Follow-up Investigation 
of Rhythm Management). The first by Ardestani et al13 was 
focused on the relationship between BMI and mortality. 
Rates of both all-cause and cardiovascular death were higher 
in patients with normal weight (5.8 and 3.1 per 100 person-
years, respectively) compared with overweight (3.9 and 1.5 
per 100 person-years, respectively) and obese (1.5 and 2.1 per 
100 person-years, respectively) patients; however, no differ-
ences were noted in the rate of stroke.13 A multivariate Cox 
regression analysis found that the relationship between both 
overweight and obese BMI categories with all-cause death 
was nonsignificant, whereas only overweight class remained 
significantly inversely associated with cardiovascular death 
(Table). Conversely, Badheka et al11 showed a significant 
inverse relationship of both all-cause and cardiovascular death 
with overweight and obese categories, using a Cox regression 
analysis that was restricted to the variables that were signifi-
cantly different at baseline.11 Moreover, a combined end point 
(all-cause death, ventricular tachycardia, ventricular fibrilla-
tion, cardiac arrest, ischemic stroke, major bleeding, systemic 
embolism, pulmonary embolism, and myocardial infarction) 
was inversely associated with both overweight (hazard ratio 
[HR], 0.73; 95% confidence interval [CI], 0.59–0.92) and 
obese (HR, 0.63; 95% CI, 0.49–0.82) categories.11
Three other RCTs found a significant inverse association 
between BMI classes and outcomes. In the subgroup of patients 
with optimal anticoagulation control (TTR>70%), Kaplan-
Meier analysis suggested a lower risk for overweight and obese 
AF patients for all-cause death and the composite outcome, but 
no association was found between overweight and obese cate-
gories after multivariate adjustment.12 A post hoc analysis com-
ing from ARISTOTLE (Apixaban for the Prevention of Stroke 
in Subjects With Atrial Fibrillation) confirmed the inverse asso-
ciation between overweight and obese categories with all-cause 
death and a composite outcome (both P<0.0001), but no influ-
ence was found for stroke/systemic embolism and major bleed-
ing outcomes (P=0.18 and P=0.11, respectively).15
Observational Studies
An ancillary analysis from the Danish Diet, Cancer and Health 
study found no relationship between the BMI categories and 
the occurrence of ischemic stroke/systemic embolism event 
both at short- and at long-term follow-up; however, after 4.9 
Figure 1. Systematic review studies selection.
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Table.  Studies Investigating the Relationship Between Atrial Fibrillation and Body Mass Index in Determining Major Adverse 
Outcomes
Study Year n BMI Classes Mean Age, y Follow-Up Outcomes*
Subgroup analyses of RCTs
  Ardestani et al13 2010 2492 Normal weight: 637 72.4 3 y (mean) Cardiovascular death
  Overweight: 965 70.7   Overweight: HR, 0.47; 95% CI, 0.29–0.76; P=0.002
  Obese: 890 66.4   Obese: HR, 0.69; 95% CI, 0.42–1.14; P=0.15
     All-cause death†
      Overweight: HR, 0.74; 95% CI, 0.53–1.03; P=0.07
     Obese: HR, 0.82; 95% CI, 0.57–1.18; P=0.3
  Badheka et al11 2010 2492 Normal weight: 637 72.4 3 y (mean) Cardiovascular death
  Overweight: 965 70.7   Overweight: HR, 0.38; 95% CI, 0.25–0.58; P<0.0001
  Obese: 890 66.4   Obese: HR, 0.65; 95% CI, 0.51–0.83; P=0.0005
     All-cause death
      Overweight: HR, 0.66; 95% CI, 0.48–0.92; P=0.01
      Obese: HR, 0.58; 95% CI, 0.42–0.80; P=0.0009
     Combined end point†‡
      Overweight: HR, 0.73; 95% CI, 0.59–0.92; P=0.007
      Obese: HR, 0.63; 95% CI, 0.49–0.82; P=0.0004
  Senoo et al14 2016 1588 Normal weight: 515 79.7 NA Stroke/SE/cardiovascular death†
  Overweight: 711 79.1   Obese: HR, 0.29; 95% CI, 0.11–0.77; P=0.01
  Obese: 362 78.6   
  Proietti et al12 2016 3651 Normal weight: 874 76 567 d Stroke†
  Overweight: 1446 73 (median)  Overweight: HR, 0.61; 95% CI, 0.37–0.99
  Obese: 1310 68   Obese: HR, 0.47; 95% CI, 0.27–0.81
   (median)  Stroke/all-cause death
      Overweight: HR, 0.69; 95% CI, 0.52–0.92
      Obese: HR, 0.59; 95% CI, 0.42–0.82
  Sandhu et al15 2016 17913 Normal weight: 4052 71.3 1.8 y (median) Stroke/SE (P=0.18)†§
  Overweight: 6702 70.1   Overweight: HR, 0.86; 95% CI, 0.68–1.08
  Obese: 7159 66.8   Obese: HR, 0.79; 95% CI, 0.61–1.02
     Major bleeding (P=0.11)§
     Overweight: HR, 0.82; 95% CI, 0.68–0.99
      Obese: HR, 0.91; 95% CI, 0.74–1.10
     All-cause death P≤0.0001§
      Overweight: HR, 0.67; 95% CI, 0.59–0.78
      Obese: HR, 0.63; 95% CI, 0.54–0.74
     Stroke/SE/MI/all-cause death P≤0.0001§
      Overweight: HR, 0.74; 95% CI, 0.65–0.84
      Obese: HR, 0.68; 95% CI, 0.60–0.78
Observational studies
  Overvad et al16 2013 3135 Normal weight: 954 67.2 4.9 y (median) Ischemic stroke/SE
  Overweight: 141 67.0   Overweight: HR, 1.14; 95% CI, 0.83–1.57; P=NS
  Obese: 767 66.9  Obese: HR, 0.98; 95% CI, 0.67–1.42; P=NS
(Continued )
 by M
A
RCO
 PRO
IETTI on M
arch 6, 2017
http://stroke.ahajournals.org/
D
ow
nloaded from
 
4  Stroke  April 2017
  Overvad et al16 
Continued
     All-cause death
      Overweight: HR, 1.31; 95% CI, 1.07–1.59; P<0.05
      Obese: HR, 1.41; 95% CI, 1.13–1.75; P<0.05
     Ischemic stroke/SE/all-cause death†
      Overweight: HR, 1.31; 95% CI, 1.10–1.56; P<0.05
      Obese: HR, 1.36; 95% CI, 1.11–1.65; P<0.05
  Wang et al17 2014 2016 Underweight: 164 70 12 mo (mean) Stroke (vs overweight)
  Normal weight: 984 69   Underweight: HR, 0.88; 95% CI, 0.4–1.73; P=0.709
  Overweight: 651 68   Normal weight: HR, 0.85; 95% CI, 0.59–1.23; P=0.387
  Obese: 217 66   Obese: HR, 0.85; 95% CI, 0.47–1.51; P=0.568
     Major bleeding (vs overweight)
      Underweight: HR, 0.65; 95% CI, 0.14–3.02; P=0.580
      Normal weight: HR, 0.74; 95% CI, 0.30–1.80; P=0.500
      Obese: HR, 0.98; 95% CI, 0.27–3.57; P=0.971
     Cardiovascular death (vs overweight)
      Underweight: HR, 2.01; 95% CI, 1.76–3.43; P=0.011
      Normal weight: HR, 1.53; 95% CI, 1.03–2.28; P=0.037
      Obese: HR, 1.28; 95% CI, 0.68–2.42; P=0.446
     All-cause death (vs overweight)†
      Underweight: HR, 1.57; 95% CI, 1.02–2.42; P=0.041
      Normal weight: HR, 1.53; 95% CI, 1.13–2.03; P=0.005
      Obese: HR, 1.03; 95% CI, 0.61–1.75; P=0.909
     Combined end point (vs overweight)‖
      Underweight: HR, 1.02; 95% CI, 0.71–1.48; P=0.899
      Normal weight: HR, 1.14; 95% CI, 0.91–1.44; P=0.247
      Obese: HR, 1.04; 95% CI, 0.72–1.52; P=0.824
  Yanagisawa et al18 2015 413 Underweight: 58 79.5 19 mo (mean) Major adverse events†¶
  Normal weight: 256 77.6   Underweight: HR, 2.45; 95% CI, 1.25–4.78; P=0.009
  Overweight/obese: 99 75.9  Overweight/obese: HR, 0.34; 95% CI, 0.13–0.89; 
P=0.029
     All-cause death
      Underweight: HR, 2.91; 95% CI, 1.12–7.60; P=0.029
      Overweight/obese: HR, 0.21; 95% CI, 0.27–1.64; 
P=0.137
  Wang et al19 2015 1286 Underweight: 386 82.08 2.1 y (median) Ischemic stroke†
  Normal weight: 3979 76.59  Underweight: HR, 1.29; 95% CI, 0.40–4.20; P=0.668
  Overweight: 1739 72.15   Overweight: HR, 1.82; 95% CI, 1.16–2.84; P=0.009
  Obese: 275 67.92   Obese: HR, 1.02; 95% CI, 0.31–3.34; P=0.969
     Thromboembolism
      Underweight: HR, 1.01; 95% CI, 0.13–7.65; P=0.996
      Overweight: HR, 0.81; 95% CI, 0.37–1.78; P=0.594
      Obese: HR, 4.83; 95% CI, 1.75–13.36; P=0.002
Table. Continued
Study Year n BMI Classes Mean Age, y Follow-Up Outcomes*
(Continued )
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  Wang et al19 
Continued
     Cardiovascular death
      Underweight: HR, 1.55; 95% CI, 0.47–5.10; P=0.336
      Overweight: HR, 0.54; 95% CI, 0.26–1.12; P=0.098
      Obese: HR, 0.66; 95% CI, 0.15–2.90; P=0.582
     All-cause death
      Underweight: HR, 2.01; 95% CI, 1.12–3.60; P=0.019
      Overweight: HR, 0.68; 95% CI, 0.47–0.99; P=0.044
      Obese: HR, 0.51; 95% CI, 0.19–1.39; P=0.189
  Kwon et al20 2016 ARIC 
cohort: 
332
Normal weight: 57 NA 6.6 y (median) Ischemic stroke/cardiovascular death†
  Overweight: 122 NA  Overweight: HR, 0.97; 95% CI, 0.71–1.33; P=NS
  Obese: 153  4.4 y (median)  Obese: HR, 0.96; 95% CI, 0.69–1.32; P=NS
 CHS 
cohort: 
335
Normal weight: 125  Ischemic stroke/cardiovascular death†
  Overweight: 136    Overweight: HR, 0.83; 95% CI, 0.64–1.06; P=NS
  Obese: 63    Obese: HR, 1.02; 95% CI, 0.74–1.41; P=NS
  Bunch et al21 2016 1558 BMI ≤20 kg/m2: 30 69.4 3 y Log-rank analysis showed that the lowest and the 
highest BMI groups had the higher risk for †composite 
outcome#, but this difference did not reach statistical 
significance (P=0.36)
  BMI 20–25 kg/m2: 296 68.7   
  BMI 26–30 kg/m2: 541 66.6   
  BMI >30 kg/m2: 691 63.6   
  Pandey et al22 2016 9606 Normal weight: 2076 80 2 y Stroke/TIA/non-CNS embolism (P=0.78)§
  Overweight: 3164 77   Overweight: HR, 0.92; 95% CI, 0.68–1.24
  Obese class I: 2173 73   Obese class I: HR, 0.94; 95% CI, 0.63–1.40
  Obese class II: 1158 70   Obese class II: HR, 0.73; 95% CI, 0.40–1.31
  Obese class III: 942 67   Obese class III: HR, 1.00; 95% CI, 0.48–2.07
   (median)  All-cause first hospitalization (P=0.39)§
      Overweight: HR, 0.97; 95% CI, 0.88–1.07
      Obese class I: HR, 1.04; 95% CI, 0.91–1.19
      Obese class II: HR, 0.98; 95% CI, 0.81–1.18
      Obese class III: HR, 0.97; 95% CI, 0.74–1.28
     All-cause death (P=0.0002)†§
      Overweight: HR, 0.81; 95% CI, 0.70–0.95
      Obese class I: HR, 0.65; 95% CI, 0.54–0.78
      Obese class II: HR, 0.85; 95% CI, 0.68–1.06
     Obese class III: HR, 0.73; 95% CI, 0.56–0.97
  Inoue et al23 2016 6379 Underweight: 386 75 2 y Thromboembolism†
  Normal weight: 3979 70   Underweight: HR, 1.22; 95% CI, 0.63–2.38; P=0.561
  Overweight: 1739 68   Overweight: HR, 0.94; 95% CI, 0.60–1.46; P=0.770
  Obese: 275 65   Obese: HR, 0.71; 95% CI, 0.22–2.27; P=0.563
(Continued )
Table. Continued
Study Year n BMI Classes Mean Age, y Follow-Up Outcomes*
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years of follow-up, both overweight and obese categories were 
positively associated with the occurrence of all-cause death 
(HR, 1.31; 95% CI, 1.07–1.59 and HR, 1.41; 95% CI, 1.13–
1.75, respectively) and the composite outcome of ischemic 
stroke/systemic embolism/all-cause death (HR, 1.31; 95% 
CI, 1.10–1.56 and HR, 1.36; 95% CI, 1.11–1.65, respectively) 
after adjustment for the CHA2DS2-VASc score (congestive 
heart failure, hypertension, age ≥75 years, diabetes mellitus, 
prior stroke, vascular disease, age 65–74, sex category).16
The study by Bunch et al21 focused on postablation follow-
up, where higher crude event rates were reported in normal 
weight patients, although after adjustments these differences 
were no longer evident. Another study, focused on the asso-
ciation of modifiable cardiovascular risk factors and outcomes 
in incident AF patients from the ARIC study (Atherosclerosis 
Risk in Communities) and CHS (Cardiovascular Health Study), 
found that no significant differences were found in event rates 
for a composite outcome of ischemic stroke and cardiovascular 
death between normal weight patients and overweight or obese 
subjects.20 Multivariate analysis confirmed no significant asso-
ciation of both overweight and obesity with outcomes.20 A sub-
group analysis for the Outcomes Registry for Better Informed 
Treatment of Atrial Fibrillation reported that a significant 
inverse association was evident only for all-cause death.22
Asian Observational Cohorts
One large observational study from a Chinese cohort found 
that both underweight and normal weight were significantly 
associated with an increased risk for both all-cause (HR, 
1.57; 95% CI, 1.02–2.42 and HR, 1.53; 95% CI, 1.13–2.03, 
respectively) and cardiovascular death (HR, 2.01; 95% CI, 
1.76–3.43 and HR, 1.53; 95% CI, 1.03–2.28, respectively) 
when compared with overweight patients.17 Despite this, no 
influence of BMI categories was reported for the occurrence 
of stroke, major bleeding, and a composite end point of sev-
eral clinically relevant events.17 Similar findings were reported 
in another single-center study of 1286 Chinese AF patients, 
where overweight patients were found to have a lower risk for 
all-cause death (HR, 0.68; 95% CI, 0.47–0.99) and a higher 
risk for underweight patients (HR, 2.01; 95% CI, 1.12–3.60).19 
A higher risk for ischemic stroke in overweight patients was 
found, even after multivariate adjustment.19
Another Japanese elderly cohort showed that being over-
weight resulted in a higher risk of death, but no influence was 
found between all-cause death and overweight/obese category.18 
However, there was an inverse association with the combined 
end point of all-cause death, stroke/transient ischemic attack, 
heart failure admission, and acute coronary syndrome (HR, 
0.39; 95% CI, 0.13–0.89; P=0.009).18 In this study, underweight 
patients were at higher risk for both major adverse events and all-
cause death.18 In a subgroup analysis from the Japanese Rhythm 
Management Trial for Atrial Fibrillation (J-RHYTHM) registry, 
underweight patients were at higher risk for both cardiovascular 
death (HR, 2.91; 95% CI, 1.47–5.75; P=0.002) and all-cause 
death (HR, 2.40; 95% CI, 1.59–3.63; P<0.001), whereas over-
weight patients had lower risk for all-cause death (HR, 0.60; 
95% CI, 0.37–0.95).23 No significant association was found for 
the obese patients nor any influence of body weight in deter-
mining thromboembolism and major bleeding.23
  Inoue et al23 
Continued
     Major bleeding
      Underweight: HR, 1.71; 95% CI, 0.96–3.05; P=0.069
      Overweight: HR, 0.74; 95% CI, 0.47–1.16; P=0.192
 Obese: HR, 0.87; 95% CI, 0.35–2.19; P=0.771
Cardiovascular death
 Underweight: HR, 2.91; 95% CI, 1.47–5.75; P=0.002
 Overweight: HR, 1.16; 95% CI, 0.58–2.30; P=0.680
 Obese: HR, 1.83; 95% CI, 0.54–6.20; P=0.332
All-cause death
 Underweight: HR, 2.40; 95% CI, 1.59–3.63; P<0.001
 Overweight: HR, 0.60; 95% CI, 0.37–0.95; P=0.031
 Obese: HR, 1.70; 95% CI, 0.84–3.44; P=0.137
ACS indicates acute coronary syndrome; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CHS, Cardiovascular Health Study; CI, confidence 
interval; CNS, central nervous system; HR, hazard ratio; MI, myocardial infarction; NA, not applicable; NS, not significant; RCT, randomized controlled trial; SE, systemic 
embolism; and TIA, transient ischemic attack.
*HR are expressed with normal weight as reference category, except where explicitly reported.
†Primary study outcome(s).
‡All-cause death, ventricular tachycardia, ventricular fibrillation, cardiac arrest, ischemic stroke, major bleeding, systemic embolism, pulmonary embolism, and 
myocardial infarction.
§Effect of BMI category.
‖All-cause death, cardiovascular death, stroke, non-CNS embolism, and major bleeding.
¶All-cause death, stroke/TIA, admission for heart failure, and acute coronary syndrome.
#All-cause death, stroke/TIA, and admission for heart failure.
Table. Continued
Study Year n BMI Classes Mean Age, y Follow-Up Outcomes*
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Meta-Analysis of Data From the NOAC Trials
Since 2011, 4 phase III RCTs comparing vitamin K antagonist 
(ie, warfarin) and NOACs have been conducted (Table II in 
the online-only Data Supplement). Data about dabigatran and 
rivaroxaban were taken from supplementary materials from 
the main papers24,25 and from the documents from regulatory 
submissions. Data on apixaban were taken from the article by 
Sandhu et al,15 but no data on BMI classes were available for 
edoxaban from the main article, subanalyses, or regulatory 
documents. All studies considered and the data collected were 
of high-quality evidence, with a overall low risk of bias iden-
tified (Table III in the online-only Data Supplement). Thus, 
Figure 2. Body mass index categories effect on (A) stroke/systemic embolic event (SEE) and (B) major bleeding. ARISTOTLE indicates 
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; CI, confidence interval; RE-LY, Randomized Evaluation of Long 
Term Anticoagulant Therapy With Dabigatran Etexilate; and ROCKET AF, Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
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information on a total of 50 031 patients were available for 
analysis: of these 12 063 patients (24.1%) were in the normal 
weight category, 19 336 patients (38.6%) in the overweight 
category, and 18 632 patients (37.2%) in the obese category.
Compared with patients with normal weight, both over-
weight and obese patients had a lower risk for the occurrence 
of the stroke/SEE outcome (OR, 0.75; 95% CI, 0.66–0.84 and 
OR, 0.62; 95% CI, 0.54–0.70, respectively; Figure 2A). When 
comparing overweight and obese patients, obese ones where 
find to have a significant lower risk of stroke/SEE (OR, 0.83; 
95% CI, 0.73–0.94; Figure 2A).
For major bleeding (Figure 2B), a significant effect of 
the BMI categories was noted only when comparing normal 
weight with obese patients, with a lower risk for obese patients 
(OR, 0.84; 95% CI, 0.72–0.98), although a moderate degree 
of heterogeneity was found (I2=58%). A significant treatment 
effect was found in normal weight patients (Figure 3A), with a 
lower risk for the stroke/SEE outcome in patients treated with 
NOACs (OR, 0.66; 95% CI, 0.56–0.78; P<0.00001). No sig-
nificant difference between NOACs and warfarin was found in 
overweight and obese patients (Figure 3B and 3C).
For major bleeding (Figure 3D through 3F), both normal 
weight (OR, 0.72; 95% CI, 0.54–0.95; P=0.02) and overweight 
(OR, 0.84; 95% CI, 0.71–1.00; P=0.05) patients treated with 
NOACs had a lower risk for outcome occurrence compared with 
warfarin (Figure 3D and 3E). In overweight patients, a moder-
ate heterogeneity was found (I2=51). No difference was found 
in obese patients for the outcome of major bleeding (Figure 3F).
Discussion
Our systematic review of the literature seems suggestive of an 
obesity paradox in AF patients, in particular for all-cause and 
cardiovascular death outcomes, notwithstanding the presence 
of associated comorbidities or more intensive pharmacologi-
cal treatments. This evidence seems to rise particularly from 
data from subgroup analyses of RCTs; conversely, observa-
tional studies with unadjusted analyses show the same evi-
dence, but after statistical adjustments, the advantage of 
overweight and obese patients is less evident in most of the 
studies. Finally, an obesity paradox was evident for stroke/
SEE outcome and major bleeding in the randomized trials of 
NOACs for stroke prevention in AF, with a treatment effect 
Figure 3. Treatment effect according to body mass index categories. Stroke/systemic embolic event (SEE): (A) normal weight; (B) over-
weight; and (C) obese. Major bleeding: (D) normal weight; (E) overweight; and (F) obese. ARISTOTLE indicates Apixaban for the Preven-
tion of Stroke in Subjects With Atrial Fibrillation; CI, confidence interval; NOAC, non–vitamin K antagonist oral anticoagulants; RE-LY, 
Randomized Evaluation of Long Term Anticoagulant Therapy With Dabigatran Etexilate; and ROCKET AF, Rivaroxaban Versus Warfarin in 
Nonvalvular Atrial Fibrillation.
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favoring NOACs compared with warfarin that was significant 
for normal weight patients.
Publications on the obesity paradox have progressively 
increased in recent years, particularly among patient with cardio-
vascular disease.4 A better prognosis, both in terms of all-cause 
and cardiovascular death, for overweight and obese patients 
has been reported for patients diagnosed with hypertension, 
coronary artery disease, congestive heart failure, and peripheral 
arterial disease.6 Indeed, our systematic review shows several 
studies in AF patients in which an obesity paradox was evident. 
This phenomenon was most evident in RCT-derived cohorts, 
whereas in observational studies, the differences in adverse 
outcomes were no longer apparent after statistical adjust-
ments for associated comorbidities in obese patients, leading 
to more intense risk factor management and hence improved 
outcomes.11,22 Trial data show that the impact of BMI catego-
ries was attenuated by good anticoagulation control, again sug-
gesting that optimized treatments could mitigate the obesity 
paradox.12,14 Such evidence altogether reaffirms the necessity 
for a more holistic approach to AF management, which would 
include treating overweight and obese AF patients.26
In a recent meta-analysis of clinical studies examining the 
relationship between BMI, AF, and outcomes, with much nar-
rower study selection criteria than our systematic review, Zhu 
et al27 found that no significant increased risk for outcomes 
was associated with overweight and obese categories in AF 
patients. Even if overweight patients had a nonsignificant 
trend for lower risk for the adverse event (risk ratio, 0.91; 95% 
CI, 0.80–1.04; P=0.18), obese patients were still at lower risk 
for stroke/SEE when compared with normal weight patients 
(risk ratio, 0.84; 95% CI, 0.72–0.98; P=0.02). This seems 
reinforced by our analysis of the recent NOAC trials, where 
an obesity paradox was evident for the occurrence of stroke/
SEE. A significant treatment effect favoring NOACs was 
found only for the normal weight patients and was nonsignifi-
cant for overweight and obese patients. In all the other studies 
reviewed, stroke and major bleeding alone were almost never 
affected by an obesity paradox.
In the non-AF patients, the relationship between BMI 
classes and stroke occurrence has been controversial. In a 
large meta-analysis comprising >2 millions of patients, both 
overweight and obese categories have associated with a 
higher risk of stroke occurrence.28 Conversely, overweight and 
obese stroke patients may have a lower risk for death after 
stroke, whereas obese patients show a lower risk for stroke 
readmissions.29
Several considerations may explain the presence of this obe-
sity paradox. First, the balance between lean and fat mass may 
be relevant, as rather than the BMI itself, the risk for adverse 
outcomes could be associated with the lean mass index. For 
example, in patients with stable coronary artery disease, the 
greatest risk for adverse events was mainly evident for those 
patients with low lean mass index when compared with those 
with high lean mass index, despite an overall high BMI.30
Another factor that may partially explain the lower risk 
associated with overweight and obesity could be age. In most 
studies, age was progressively lower in overweight and obese 
patients, compared with normal weight subjects. In most stud-
ies in which the obesity paradox was confirmed, a difference in 
age between the categories was more pronounced. The length 
of follow-up could also determine the occurrence of adverse 
events.31 As evident from our results, those studies that failed 
to show an obesity paradox were those with the longest fol-
low-up duration. Moreover, studies that only considered BMI 
at baseline did not examine the time-dependent changes nor 
factors that can attenuate and modify BMI, including physical 
activity and cardiorespiratory fitness. Indeed, the latter have 
been associated with lower weight and a lower risk of devel-
oping AF.9,10
Some specific considerations are needed for the Asian pop-
ulations. Underweight is considered to be a risk factor for a 
higher risk of bleeding in Asian AF patients, leading to spe-
cific recommendations.32 Our systematic review did not verify 
this perception, with the underweight category not being asso-
ciated with an increased risk of major bleeding but conversely 
being associated with a higher risk for both cardiovascular 
and all-cause death. The Fushimi AF registry reported that AF 
patients with low body weight had a higher risk for stroke/
SEE and all-cause death, whereas no influence was evident 
for major bleeding.33 The mortality risk associated with being 
overweight has been confirmed in the general population.34
Limitations
The role of comorbidities and concomitant medications can-
not be fully accounted for, despite multivariate adjustments. 
In observational studies, BMI reporting could be inaccurate. 
Hence, more studies specifically examining this issue, per-
haps with time-dependent changes in BMI and investigating 
the balance between lean and fat body mass, are still needed 
to confirm the obesity paradox in AF. Furthermore, our 
exclusion of non-English studies and conference abstracts 
could have generated some selection bias. Our conclusions 
do not advocate the maintenance of a higher BMI in AF 
patients but emphasize the need of a holistic approach to AF 
management.
In conclusion, there may be an obesity paradox in AF 
patients, particularly for all-cause and cardiovascular death 
outcomes. Despite this, data from observational studies show 
that after full adjustments for baseline characteristics, an 
obesity paradox is no longer evident, highlighting the role of 
comorbidities and risk factor management in influencing the 
obesity paradox and thus leaving this question still partially 
unanswered. However, an obesity paradox was evident for 
stroke/SEE outcome in NOACs trials, with a treatment effect 
significantly favoring NOACs over warfarin in normal weight 
patients. Further evidence from large prospective studies may 
further clarify this relationship.
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SUPPLEMENTAL	METHODS	
In	order	to	perform	this	systematic	review,	the	following	criteria	were	considered:	i)	both	
randomized	clinical	trials	(RCTs)	and	observational	cohort	studies	focusing	on	patients	with	
established	AF;	ii)	specific	data	on	BMI	and	BMI	categories;	iii)	studies	reporting	data	on	
long-term	follow-up	observations.		Exclusion	criteria	were:	i)	conference	abstracts,	letters,	
comments,	case	reports,	and	editorials;	ii)	studies	not	published	in	English.			
	
Search	strategy	
A	comprehensive	literature	search	was	performed	using	PubMed	and	Scopus	databases,	up	
to	30th	June	2016.	Search	terms	included	“atrial	fibrillation”,	“obesity”,	“body	mass	index”,	
“BMI”,	“stroke”,	“major	bleeding”,	“death”	and	“outcomes”.	The	electronic	search	was	
carried	out	for	peer-reviewed	journals	and,	if	applicable,	some	further	additional	references	
were	gathered	from	searches	through	bibliographies	of	identified	papers	and	from	authors’	
personal	knowledge.	
	
Data	to	perform	the	meta-analysis	on	NOACs	trials	were	collected	directly	from	the	original	
papers	reporting	results	(or	subgroup	analysis)	of	phase	III	trials	on	dabigatran,	rivaroxaban,	
apixaban	and	edoxaban	in	non-valvular	AF1–4	or	throughout	extensive	revision		of	approval	
documentation	available		through	Food	and	Drug	Administration	(http://www.fda.gov)	and		
European		Medicines	Agency	(http://www.ema.europa.eu/ema/)		websites	
	
Data	extraction	
Literature	search	for	the	systematic	review	was	performed	by	two	co-authors	(MP	and	PC)	
and	data	were	extracted	independently.	In	any	case	of	discrepancies,	disagreement	was	
3	
	
resolved	with	collegial	discussion.	Data	for	the	NOACs	meta-analysis	were	searched	and	
collected	independently	by	two	co-authors	(MP	and	EG).	For	the	systematic	review,	data	on	
sample	size	according	to	BMI	categories,	mean	or	median	age,	follow-up	time	and	adverse	
outcomes	were	collected.	For	the	meta-analysis,	data	on	sample	size	according	to	BMI	
categories	and	number	of	adverse	events	were	collected.	Outcomes	considered	were	
stroke/systemic	embolic	event	(SEE)	and	major	bleeding.	In	any	case	of	discrepancies,	
disagreement	was	again	resolved	with	collegial	discussion.		
	
BMI	categories	
BMI	categories	were	defined	as	follows	in	most	of	the	studies:	i)	underweight:	BMI	<18.5	
kg/m2;	ii)	normal	weight:	BMI	18.5-24.9	kg/m2;	iii)	overweight:	BMI	25.0-29.9	kg/m2;	iv)	
obese:	BMI	≥30.0.	In	the	study	by	Pandey	et	al5,	obesity	classes	were	defined	as	follows:	i)	
obesity	class	I:	BMI	30.0-34.9	kg/m2;	ii)	obesity	class	II:	BMI	35.0-39.9	kg/m2;	iii)	obesity	class	
III:	BMI	≥40.0	kg/m2.	In	the	study	by	Bunch	et	al.6	BMI	were	defined	as:	BMI	≤20	kg/m2;	BMI	
20-25	kg/m2;	BMI	26-30	kg/m2;	BMI	>30	kg/m2.	
	
Quality	of	studies	
Overall	quality	of	studies	was	assessed	to	minimized	bias	presence.	Such	evaluation	was	
independently	assessed	by	two	co-authors	(MP	and	PC)	for	the	studies	included	in	the	meta-
analysis.	Bias	assessment	has	been	performed	according	to	the	Agency	for	Healthcare	
Research	and	Quality	(AHRQ)	recommendations7.	An	overall	low	risk	of	bias	qualified	for	
high	quality	of	evidence.	
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Statistical	Analysis	
All	statistical	analyses	were	undertaken	using	Review	Manager	(RevMan)	version	5.3	(The	
Cochrane	Collaboration	2014,	Nordic	Cochrane	Centre	Copenhagen,	Denmark).	Outcomes	
from	each	trials	were	pooled	and	compared	using	a	fixed-effect	or	random-effect	model	
according	to	the	heterogeneity	between	all	included	RCTs.	Subgroups	were	considered,	in	
relation	to	NOAC	doses.	Odds	ratio	(OR)	and	corresponding	95%	confidence	intervals	(CI)	
were	calculated	for	each	outcome	and	RCT	separately.	When	necessary,	the	numbers	of	
outcome	events	were	calculated	using	event	rates,	sample	size	and	follow-up	duration.	A	
low	P-value	indicates	significant	heterogeneity	among	all	RCTs	included,	with	a	cut-off	at	
0.10.	The	I2-statistic	was	quantified	to	describe	the	percentage	of	variation	across	all	
included	trials.	When	an	I2	of	>50%	(representing	high	inconsistency)	was	observed,	a	
random-effects	model	was	used	to	analyse	for	interpretation.	A	p-value	<0.05	was	
considered	statistically	significant.	
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SUPPLEMENTAL	TABLES	
Table	I:	PRISMA	Checklist	
Section/topic  # Checklist item  
Reported 
on page 
# 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
4, Suppl. 
Material 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
Suppl. 
Material 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Suppl. 
Material 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
Suppl. 
Material 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
Suppl. 
Material 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Suppl. 
Material 
6	
	
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
Suppl. 
Material 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
Suppl. 
Material 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
Suppl. 
Material 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Suppl. 
Material 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
Suppl. 
Material 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
Suppl. 
Material 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
Suppl. 
Material 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Fig. 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
4-8 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
9 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9-10 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
9-10 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  9 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
NA 
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DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
10 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
10-13 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
14 
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Table	II:	General	characteristics	of	NOACs	Phase	III	RCTs	
TRIAL	 RE-LY1	 ROCKET-AF2	 ARISTOTLE3	
ENGAGE	
AF-TIMI	484	
Year	 2009	 2011	 2011	 2013	
Study	design	 Open-label	 Double-blind	 Double-blind	 Double-blind	
Sample,	n	 18,113	 14,264	 18,201	 21,105	
Median	age,	years	 71.5	(Mean)	 73.0	 70.0	 72.0	
NOAC	
Dabigatran	150 mg	
or	110 mg	twice	daily	
Rivaroxaban	20 mg	
or	15 mg	once	daily	
Apixaban	5 mg	
or	2.5 mg	twice	daily	
Edoxaban	60	mg	
or	30	mg	once	daily	
Control	drug	
Warfarin	dose-adjusted	
(INR	2.0-3.0),	once	daily	
Warfarin	dose-adjusted	
(INR	2.0-3.0),	once	daily	
Warfarin	dose-adjusted	
(INR	2.0-3.0),	once	daily	
Warfarin	dose-adjusted		
(INR	2.0-3.0),	once	daily	
Mean	TTR,	%	 64.0	 55.0	 62.2	 64.9	
Mean	CHADS2		score		 2.1	 3.5	 2.1	 2.8	
Median	FU,	years	 2.0	 1.9	 1.8	 2.8	
Legend:	FU=	follow-up;	INR=international	normalized	ratio;	NOAC=	non-vitamin	K	antagonist	oral	anticoagulant;	TTR=time	in	the	therapeutic	
range.
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Table	III:	Risk	of	bias	assessment	
	 Selection	
Bias*	
Performance	
Bias†	
Attrition	
Bias‡	
Detection	
Bias§	
Reporting	
Biasǁ	
Overall	Risk	
of	Bias#	
Connolly	et	al.	 L	 L	 L	 L	 L	 L	
Patel	et	al.	 L	 L	 L	 L	 L	 L	
Sandhu	et	al.	 L	 L	 L	 L	 L	 L	
Legend:	L=	Low;	*Randomization,	allocation	concealment,	sequence	generation,	control	for	
confounders	in	cohort	studies;	†Fidelity	to	protocol,	unintended	interventions	or	co-
interventions;	‡Incomplete	outcome	data,	intention-to-treat	analysis,	and	completeness	of	
follow-up;	§Blinding	of	outcome	assessors,	especially	with	subjective	outcome	assessments,	
bias	in	inferential	statistics,	valid	and	reliable	measures;	ǁSelective	outcome	reporting	
evaluation	by	comparing	study	report	and	(a)	protocol	or	(b)	outcomes	prespecified	in	
methods;	#Overall	risk	of	bias	was	defined	“low”	whether	3	out	of	5	bias	were	find	“low”.	
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